Literature DB >> 33634479

Cardiac extracellular volume fraction in cats with preclinical hypertrophic cardiomyopathy.

Ryan C Fries1, Saki Kadotani1, Stephanie C J Keating1, Jonathan P Stack1.   

Abstract

BACKGROUND: Cardiac magnetic resonance imaging (CMR) allows for detection of fibrosis in hypertrophic cardiomyopathy (HCM) by quantification of the extracellular volume fraction (ECV). HYPOTHESIS/
OBJECTIVES: To quantify native T1 mapping and ECV in cats. We hypothesize that native T1 mapping and ECV will be significantly increased in HCM cats compared with healthy cats. ANIMALS: Seventeen healthy and 12 preclinical HCM, age-matched, client-owned cats.
METHODS: Prospective observational study. Tests performed included indirect blood pressure, CBC, biochemical analysis including total thyroid, urinalysis, transthoracic echocardiogram, and CMR. Cats were considered healthy if all tests were within normal limits and a diagnosis of HCM was determined by the presence of left ventricular concentric hypertrophy ≥6 mm on echocardiography.
RESULTS: There were statistically significant differences in LV mass (healthy = 5.87 g, HCM = 10.3 g, P < .0001), native T1 mapping (healthy = 1122 ms, HCM = 1209 ms, P = .004), and ECV (healthy = 26.0%, HCM = 32.6%, P < .0001). Variables of diastolic function including deceleration time of early diastolic transmitral flow (DTE), ratio between peak velocity of early diastolic transmitral flow and peak velocity of late diastolic transmitral flow (E : A), and peak velocity of late diastolic transmitral flow (A wave) were significantly correlated with ECV (DTE; r = 0.73 P = .007, E : A; r = -0.75 P = .004, A wave; r = 0.76 P = .004). CONCLUSIONS AND CLINICAL IMPORTANCE: Quantitative assessment of cardiac ECV is feasible and can provide additional information not available using echocardiography.
© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.

Entities:  

Keywords:  T1 mapping; cardiac fibrosis; feline; magnetic resonance imaging; strain

Mesh:

Year:  2021        PMID: 33634479      PMCID: PMC7995366          DOI: 10.1111/jvim.16067

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  41 in total

1.  Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans.

Authors:  Andrew S Flett; Martin P Hayward; Michael T Ashworth; Michael S Hansen; Andrew M Taylor; Perry M Elliott; Christopher McGregor; James C Moon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

2.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy.

Authors:  Christopher T Sibley; Radwa A Noureldin; Neville Gai; Marcelo Souto Nacif; Songtao Liu; Evrim B Turkbey; James O Mudd; Rob J van der Geest; João A C Lima; Marc K Halushka; David A Bluemke
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

3.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  James C C Moon; Emma Reed; Mary N Sheppard; Andrew G Elkington; Siew Yen Ho; Margaret Burke; Mario Petrou; Dudley J Pennell
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

4.  Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.

Authors:  Ramón Martos; John Baugh; Mark Ledwidge; Christina O'Loughlin; Carmel Conlon; Anil Patle; Seamas C Donnelly; Kenneth McDonald
Journal:  Circulation       Date:  2007-02-05       Impact factor: 29.690

5.  CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF.

Authors:  Mao-Yuan M Su; Lian-Yu Lin; Yao-Hui E Tseng; Chin-Chen Chang; Cho-Kai Wu; Jiunn-Lee Lin; Wen-Yih I Tseng
Journal:  JACC Cardiovasc Imaging       Date:  2014-09-17

6.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.

Authors:  Leah Iles; Heinz Pfluger; Arintaya Phrommintikul; Joshi Cherayath; Pelin Aksit; Sandeep N Gupta; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

7.  Left ventricular extracellular volume fraction and atrioventricular interaction in hypertension.

Authors:  Jonathan C L Rodrigues; Tamas Erdei; Amardeep Ghosh Dastidar; Gergley Szantho; Amy E Burchell; Laura E K Ratcliffe; Emma C Hart; Angus K Nightingale; Julian F R Paton; Nathan E Manghat; Mark C K Hamilton
Journal:  Eur Radiol       Date:  2018-09-19       Impact factor: 5.315

8.  Feasibility of radial and circumferential strain analysis using 2D speckle tracking echocardiography in cats.

Authors:  Hiroshi Takano; Tomomi Isogai; Takuma Aoki; Yoshito Wakao; Yoko Fujii
Journal:  J Vet Med Sci       Date:  2014-11-06       Impact factor: 1.267

Review 9.  Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review.

Authors:  Philip Haaf; Pankaj Garg; Daniel R Messroghli; David A Broadbent; John P Greenwood; Sven Plein
Journal:  J Cardiovasc Magn Reson       Date:  2016-11-30       Impact factor: 5.364

10.  Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy.

Authors:  Sairia Dass; Joseph J Suttie; Stefan K Piechnik; Vanessa M Ferreira; Cameron J Holloway; Rajarshi Banerjee; Masliza Mahmod; Lowri Cochlin; Theodoros D Karamitsos; Matthew D Robson; Hugh Watkins; Stefan Neubauer
Journal:  Circ Cardiovasc Imaging       Date:  2012-10-15       Impact factor: 7.792

View more
  2 in total

1.  Cardiac extracellular volume fraction in cats with preclinical hypertrophic cardiomyopathy.

Authors:  Ryan C Fries; Saki Kadotani; Stephanie C J Keating; Jonathan P Stack
Journal:  J Vet Intern Med       Date:  2021-02-26       Impact factor: 3.333

2.  The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy.

Authors:  Mark D Kittleson; Etienne Côté
Journal:  J Feline Med Surg       Date:  2021-11       Impact factor: 2.015

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.